1.27 N/A 0.58% 0.00% Distribution costs (41.75 ) (24.14 ) (17.61 ) 72.95% (19.11%) (13.74%) Administrative expenses (95.74 ) (94.34 ) (1.40 ) 1.48% (43.82%) (53.71%) Other Expenses Impairment loss of
-27.5% -24.5% 2,120.4 1,782.4 -15.9% Other income 31.8 15.9 22.9 -28.1% +44.1% 51.7 38.7 -25.1% Selling and distribution expenses 587.2 536.7 463.7 -21.0% -13.6% 1,175.1 1,000.4 -14.9% Administrative
) % Revenue from sales and service 1,788.5 2,025.3 1,187.1 (236.8) (11.7) 601.4 50.7 Cost of sales and service 1,499.5 1,686.8 998.7 (187.3) (11.1) 500.8 50.1 Selling and distribution expenses 73.7 78.7 52.0
sales staffs, advertising media fee for product promotion, distribution fee paid to Zuellig Pharma Ltd. under the Distribution Agreement and compensation for distribution of company’ s products in the
0.00 12.21 N/A 6.95% 0.00% Revenues from reduction of defaulted interest under the Court’s order 16.66 0.00 16.66 N/A 9.48% 0.00% Distribution costs (24.14 ) (26.13 ) (1.99 ) 7.62% (13.74%) (8.83
profitability. The Company has added new growth engines through both organic and inorganic expansion which enable MACO to achieve an outstanding top and bottom line performance compared to the same period last
accounting standard, the Company is required to record lease contract which has outstanding period of more than 12 months in the financial statements. The affected lease contracts related to the lease of space
outbreak control measures are being gradually relaxed and Vaccination is more progressive. 2). The effect of outstanding demand from the previous period and 3). Government measures that continue to bolster